CytomX Therapeutics (NasdaqGS:CTMX) 2026 Conference February 11, 2026 04:30 PM ET Company ParticipantsChris Ogden - CFOConference Call ParticipantsMichael Schmidt - Senior Biotech AnalystMichael Schmidtthis next fireside chat. My name is Michael Schmidt, senior biotech analyst with Guggenheim, and it's my great pleasure to welcome Chris Ogden, Chief Financial Officer of CytomX. So CytomX is a new coverage here, new research coverage at Guggenheim for us. It's a story we're really excited about, especially t ...

Summary of Science Applications International (SAIC) FY Conference Call Company Overview - **Company**: Science Applications International Corporation (SAIC) - **Ticker**: NasdaqGS:SAIC - **Date of Call**: February 11, 2026 Key Points Industry and Market Context - The company operates in the defense and technology services sector, focusing on enterprise IT and mission-oriented engineering solutions [4][113]. - The macro environment is described as confusing, with uneven funding and slow contract execution impacting revenue growth [10][12]. Financial Performance and Guidance - SAIC initially projected revenue growth of flat to +3% for FY 2027 but revised guidance downwards due to contract losses, specifically: - Loss of the Army Corps of Engineers recompete (3% of revenue) - Loss of Cloud One recompete (1% of revenue) - The revised guidance indicates a nominal growth of approximately -1% for FY 2027 [4][22][24]. - Q4 revenue was reported to be light by about 2%, attributed to several factors including shutdown-related disruptions and delays in material availability [13][21]. Revenue Impact and Projections - The total impact from the two major contract losses is estimated at $275 million, with $200 million from CastleNet and $75 million from Cloud One [32][38]. - On-contract growth is expected to stabilize between 1% and 3% throughout the year, which is lower than historical averages [49][51]. - The company anticipates potential tailwinds from new contracts won, including: - Air Force TENCAP ($1 billion) - Navy ATSO ($350 million over 5 years) - Army OSINT ($75 million) [53][56]. Strategic Focus and Challenges - SAIC is focusing on being selective in bidding for contracts, particularly in the commoditized enterprise IT market, where margins are lower [113][120]. - The company aims to pivot towards fixed-price contracts and mission-oriented work, which have shown higher win rates [135][143]. - The backlog remains healthy, with expectations to finish FY 2026 with a book-to-bill ratio north of 1.0 [70][74]. Future Opportunities - The defense budget is projected to exceed $1 trillion, with SAIC focusing on mission data, cloud-based command and control, and modernization of legacy systems as key growth areas [184][191]. - The company is exploring M&A opportunities, particularly in data-focused AI and intelligence sectors, while being cautious about capital allocation due to stock valuation concerns [240][241]. Leadership and Culture - The search for a permanent CEO is ongoing, with a focus on finding an execution-oriented leader who can create shareholder value [276][280]. - The company is investing in employee training and development to retain top talent during its transformation process [302][310]. Risks and Considerations - The company faces risks related to recompete contracts, with approximately 1% of revenue up for recompete in the next 12 months [98][100]. - The procurement environment has shown signs of unpredictability, impacting submit volumes and contract negotiations [105][106]. Conclusion - SAIC is navigating a challenging environment with a focus on strategic growth areas and operational efficiency. The company is committed to transforming its portfolio and enhancing its competitive position in the defense sector while managing risks associated with contract recompetes and market dynamics [292][295].

Travere Therapeutics (NasdaqGM:TVTX) 2026 Conference February 11, 2026 04:00 PM ET Company ParticipantsChris Cline - CFOEric Dube - President and CEOConference Call ParticipantsVamil Divan - Biopharma AnalystVamil DivanAll right, I think we're ready to get started. So, thanks everyone for joining us for this year's Biotech Summit here at Guggenheim. I'm Vamil Divan, one of the biopharma analysts here. Next up in this room, we have the Travere Therapeutics team. Next to me, Eric Dube, the President and CEO, ...

Entrada Therapeutics (NasdaqGM:TRDA) 2026 Conference February 11, 2026 04:00 PM ET Company ParticipantsDipal Doshi - CEOConference Call ParticipantsDebjit Chattopadhyay - Managing Director and Senior Biotech AnalystDebjit ChattopadhyayAfternoon, and thank you for joining us at Guggenheim's 2026 Emerging Outlook Biotech Summit. I'm Debjit, one of the therapeutic analysts, and next presenting company is Entrada Therapeutics. Joining us from Entrada is the CEO, Dipal Doshi. Thank you so much for making time fo ...

Neumora Therapeutics (NasdaqGS:NMRA) 2026 Conference February 11, 2026 04:00 PM ET Company ParticipantsHelen Rubinstein - VP of Investor Relations and Corporate CommunicationsJosh Pinto - PresidentNick Brandon - Chief Scientific OfficerConference Call ParticipantsDalma Khayati - Biotechnology Research AnalystYatin Suneja - Biotechnology Research AnalystYatin SunejaGood afternoon, everyone. Welcome to Guggenheim Emerging Outlook Biotech Summit, 2026. It is my pleasure to welcome our next presenting company, ...

Zentalis Pharmaceuticals (NasdaqGM:ZNTL) 2026 Conference February 11, 2026 03:30 PM ET Company ParticipantsIngmar Bruns - CMOJulie Eastland - President and CEOConference Call ParticipantsMichael Schmidt - Senior Biotech AnalystMichael SchmidtKicking off the next fireside chat here. My name is Michael Schmidt, Senior Biotech Analyst with Guggenheim, and I'm really happy to welcome, Julie Eastland, President and CEO of Zentalis, and she's joined by, Ingmar Bruns, Chief Medical Officer. Welcome. Thanks for joi ...

Celldex Therapeutics (NasdaqCM:CLDX) 2026 Conference February 11, 2026 03:30 PM ET Company ParticipantsAnthony S. Marucci - President and CEODiane Young - CMOTibor Keler - Chief Scientific OfficerConference Call ParticipantsYatin Suneja - Biotech AnalystYatin SunejaEveryone, welcome to Guggenheim Emerging Outlook Biotech Summit 2026. My name is Yatin Suneja, one of the biotech analysts here at the firm. My pleasure to introduce my next presenting company, Celldex Therapeutics. From the company, we have thre ...

AnaptysBio Conference Call Summary Company Overview - **Company**: AnaptysBio (NasdaqGS:ANAB) - **Event**: Guggenheim Emerging Outlook Biotech Summit 2026 - **Date**: February 11, 2026 Key Points Company Separation - AnaptysBio is in the process of separating its biopharma operations from its core royalty portfolio, targeting a Q2 2026 separation date [4] - The biopharma business will include three clinical stage programs: - Rosnilimab (completed Phase 2b study in RA, moving to Phase 3) [5] - CD122 program (two studies: one ongoing in celiac disease, one initiating in EOE) [5] - ANB101 (BDCA2 modulator, ongoing Phase 1 trial) [5] - The new biopharma entity will be publicly traded and capitalized adequately to support its clinical trials [5] Royalty Portfolio - The royalty business is anchored on two programs: - Jemperli (royalty from GSK, projected to generate $1.8 billion in revenue this year) [6] - Imsidolimab (outlicensed to Vanda, seeking accelerated approval) [6] - Jemperli's growth rate is expected to remain strong, with significant market share capture anticipated due to its survival data compared to competitors [8][10] - GSK's guidance suggests potential peak sales of over $2.7 billion, with a long runway for growth [14] Clinical Programs - **Rosnilimab**: - End-of-phase 2 meeting with the FDA scheduled to define the size of the Phase 3 program [138] - Focus on securing funding for the Phase 3 program while prioritizing the separation of the companies [146] - **CD122 Program**: - Differentiated mechanism targeting both IL-15 and IL-2 signaling, with applications in celiac disease and eosinophilic esophagitis (EOE) [57][68] - Ongoing studies in celiac disease aim to demonstrate therapeutic benefits for patients with gluten exposure [97][103] - EOE studies will focus on both eosinophil reduction and symptomatic impact, with data expected in 2027 [114] - **ANB101 (BDCA2 Modulator)**: - Competing with a first-generation BDCA2 in Phase 3 trials by Biogen, with AnaptysBio's drug showing a differentiated depletion profile [121][125] Market Potential - Celiac disease has over 2 million patients in the U.S., with approximately 250,000 non-compliant to a gluten-free diet, representing a significant market opportunity [97] - The EOE market is also substantial, with a need for effective treatments beyond existing options [114] Financial Considerations - AnaptysBio has $310 million in cash at the beginning of the year, sufficient to fund operations into 2028 if allocated to the biopharma business [51] - The company has been actively repurchasing stock, indicating confidence in its valuation and future prospects [46] Regulatory Environment - The company is navigating ongoing litigation related to Jemperli, but it does not impact the planned separation of the biopharma business [16][18] Conclusion - AnaptysBio is positioned for significant growth through its clinical programs and the separation of its business units, with a strong focus on capitalizing on its royalty portfolio and advancing its biopharma pipeline. The upcoming data releases and regulatory meetings will be critical in shaping the company's future trajectory.

Voyager Technologies (NYSE:VOYG) FY Conference February 11, 2026 02:50 PM ET Speaker1Well, thank you guys. Really appreciate, all of you for attending the TD Cowen Aerospace and Defense Conference. My name is Gautam Khanna. I'm the TD Cowen Aerospace and Defense Research Analyst. We're very privileged to have with us representatives from Voyager Technologies, a relatively new IPO. We have with us Chief Strategy Officer Wallace Lockery and Adi Padva, Adi Padva.Speaker2Good.Speaker1My name is Gautam Khanna, a ...

Summary of International Battery Metals Conference Call Company Overview - **Company Name**: International Battery Metals (IBAT) - **Stock Symbols**: IBAT on TSXV, IBAT.F on OTCQB [3][2] - **Headquarters**: Houston, Texas [3] - **Founded**: 2018 [3] - **Market Capitalization**: Approximately $36 million [3] - **Cash Balance**: Approximately $9 million as of December 31 [3] Industry Context - **Industry**: Lithium extraction and battery technology [3] - **Critical Mineral**: Lithium is classified as a critical mineral with diverse applications, primarily driven by the battery industry [4] - **Demand Growth**: Lithium demand is projected to grow from 1.6 million metric tons annually to between 4-6.5 million metric tons by 2035, representing a 3-5x increase over the next decade [9][17] Core Technology and Business Model - **Direct Lithium Extraction (DLE)**: The company specializes in DLE technology, which is modular and allows for lower capital intensity and faster execution times compared to traditional lithium extraction methods [3][7][8] - **Modular Technology**: Enables construction of plants off-site, reducing costs and allowing for staged development [7][8] - **Unique Media**: The proprietary media used in the DLE process is sourced and manufactured in the U.S., providing high selectivity and efficiency in lithium extraction [18][19] Market Dynamics - **Nearshoring Trend**: There is a global movement to secure critical mineral supply chains away from China, which dominates the lithium supply chain [5][14] - **Supply Chain Rebalancing**: The geopolitical landscape is driving a shift towards local sourcing of lithium, with increased focus on U.S. and allied nations [12][13] Financial and Operational Highlights - **Lithium Price Recovery**: Lithium prices have rebounded from lows of approximately $8,500 per metric ton to around $20,000 per metric ton, improving project economics [28][29] - **Project Deployment**: The company is focused on redeploying its existing plant, which has already generated over 25 tons of battery-grade lithium carbonate [20][21] Future Outlook - **Growth Projections**: DLE technology is expected to account for 15%-20% of the lithium supply market over the next decade, potentially providing 1 million tons of lithium annually by 2035 [17] - **Strategic Partnerships**: The company is exploring various revenue models, including licensing, service models, and project participation, to align with customer needs [25][26][27] - **R&D and Commercial Readiness**: The company is currently commercial-ready and continues to improve its technology, focusing on larger columns to enhance efficiency [33][34] Key Challenges and Considerations - **Market Volatility**: The lithium market is subject to price fluctuations, and the company aims to be a low-cost operator to remain competitive [35][36] - **Skepticism Around DLE**: Addressing concerns about the viability of DLE technology is crucial for gaining customer and investor confidence [36][37] Conclusion - **Management Focus**: The management team is committed to executing the company's strategy and capitalizing on the growing lithium demand driven by electric vehicles and energy storage solutions [30][31] - **Positive Catalysts**: Key catalysts for the next 12 months include the deployment of the existing plant and potential new projects in various regions [30][32]